15-Year study to uncover hidden heart risks in breast cancer therapy
NCT ID NCT05078190
First seen Nov 06, 2025 · Last updated May 13, 2026 · Updated 29 times
Summary
This study follows 200 women with breast cancer who are receiving chemotherapy drugs doxorubicin or trastuzumab. Researchers want to understand how these treatments affect the heart over time and how factors like race, income, and access to healthcare play a role. Participants will have heart ultrasounds, blood tests, and answer questions about their health for up to 15 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.